Pillar Point antitrust complaint readied by FTC investigators, Summit says.
This article was originally published in The Gray Sheet
PILLAR POINT ANTITRUST COMPLAINT READIED BY FTC INVESTIGATORS, Pillar Point partner Summit Technology discloses in its second quarter financial report. Federal Trade Commission investigators have "reason to believe that a violation of the Federal Trade Commission Act may have occurred and that [they are] prepared to recommend that the Commission issue an administrative complaint under the act," Summit says.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.